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Ligation of both TLR2 and 9 on human cells has been shown to
be associated with the development of T-reg cells and/or
tolerance [5, 6]. We found that HSV infection conferred
protection against atopy among Finnish children only.
Besides the fact that atopy is infrequent in Russian Karelia,
the overall exposure to microorganisms is overwhelming and
the impact of saprophytes and other pathogens may well
override the possible effects of HSV on the Russian side.
In summary, in an area with a relatively low microbial burden
such as Finnish Karelia, herpes simplex virus appears to be able
to exert immunomodulatory potential, which may have implica-
tions for the occurrence of atopy. This finding confirms the result
shown previously in two other Western populations [7, 8].
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Variation in the tumour necrosis factor gene is not
associated with susceptibility to COPD
To the Editors:
In a recent issue of the European Respiratory Journal, TANAKA
et al. [1] studied polymorphisms in the tumour necrosis factor
(TNF) and lymphotoxin A genes with respect to their effect on
lung function of smokers, and failed to find any association with
chronic obstructive pulmonary disease (COPD) phenotypes.
TANAKA et al. [1] acknowledge that their work is not a true case–
control study, but that it would be better described as an
investigation of genetic contribution to disease severity. There
have been several studies of variation in TNF with respect to
susceptibility to COPD, although many of these have used
relatively small sample sizes and are therefore underpowered,
and so are likely to lead to results that cannot be replicated.
As part of a European Union collaborative project, we have
studied polymorphisms within the TNF gene in a large
collection of well-characterised Caucasian COPD patients
(n51,018) and control subjects (n5911). COPD cases and
TABLE 1 Frequency of single nucleotide polymorphisms
(SNPs) genotyped in the tumour necrosis factor
gene#
COPD patients Controls
rs1799964" (T-1031C) 0.207 0.193
rs1800629" (G-308A) 0.179 0.178
rs361525" (G-238A) 0.055 0.049
rs1800610 (G489A) 0.096 0.096
rs3093662 (A851G) 0.084 0.077
rs1800628 (G3512A) 0.127 0.119
COPD: chronic obstructive pulmonary disease. #: numbering with respect to
the transcription start site is shown in parentheses; ": SNPs studied by TANAKA
et al. [1].
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control subjects were recruited from six European centres, as
previously reported [2]. The characteristics of each group are
summarised as follows, with data expressed as mean¡SD,
where appropriate. Controls: 63.5% male; age 60.8¡8.9 yrs;
smoking history 38.6¡17.4 pack-yrs; forced expiratory volume
in one second (FEV1) 95.3¡10.9% predicted; FEV1/forced vital
capacity (FVC) 77.9¡4.9%. COPD cases: 69.6% male; age
65.8¡8.2 yrs; smoking history 48.9¡23.6 pack-yrs; FEV1
43.0¡15.3% pred; FEV1/FVC 47.5¡12.2%.
Six single nucleotide polymorphisms (SNPs) in TNF (table 1)
were genotyped using Taqman1 probes (Geneservice Ltd,
Babraham, UK). Primer and probe sequences are available on
request. As quality control measures for the genotyping, 2% of
samples of known genotype were included and 10% of
samples were present in duplicate to check for concordance.
All SNPs were in Hardy–Weinberg equilibrium.
The association of single SNPs with COPD was carried out
using a Chi-squared analysis; none of the SNPs showed a
significant difference in genotype frequency between cases and
controls (po0.331). Linear regression analysis in cases and
controls was used to identify any possible effect of TNF
genotype on FEV1 (with age, smoking history and sex as
covariates). Using a stringent cut-off, this also failed to find any
significant effect, with the lowest p-value being obtained for
rs1800628 in controls only p50.010. Allowing for multiple
testing, this is unlikely to be a true association.
A case–control analysis of TNF haplotypes was carried out
according to [3]. Haplotypes of the TNF SNPs are shown in
table 2. This analysis identified a total of 10 haplotypes, seven
of which were present at a frequency .2%. There was no
significant difference in the frequency of these haplotypes
between COPD cases and controls (global score statistic52.024,
7 degrees of freedom; p50.959). Similarly, using the omnibus
test performed over all haplotypes in the SAS procedure PROC
HAPLOTYPE [4], none of the possible subsets of the six SNPs
showed a significant relationship with COPD.
In this large case–control study using well-characterised COPD
patients and controls, we failed to find any association of the
TNF polymorphisms with the development of COPD. This is in
agreement with other smaller studies in Caucasian populations
[5–8], although many studies have only considered the -308
SNP. One study, using 169 Caucasian COPD patients and 358
controls, showed an increase of the 489_GA genotype in the
COPD patients with an associated odds ratio of 1.9 [9];
however, this is not replicated in the current study, suggesting
that it may have been a false-positive result.
For allele frequencies ranging 0.05–0.20 (using a dominant
model and a50.01), the current study has .80% power to
detect minimum effect sizes of 1.4–1.65. The fact that we see no
association with any of the tumour necrosis factor single
nucleotide polymorphisms or haplotypes makes it highly
unlikely that polymorphisms in this gene play a major role
in the susceptibility to chronic obstructive pulmonary disease.
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TABLE 2 Haplotypes of tumour necrosis factor single nucleotide polymorphisms and frequency in cases and controls
Polymorphism Frequency
rs1799964 rs1800629 rs361525 rs1800610 rs3093662 rs1800628 Controls COPD cases
1 T A G G A G 0.058 0.052
2 T G G G A G 0.502 0.489
3 T G G A A G 0.095 0.095
4 T G G G G G 0.028 0.029
5 A G G G A G 0.146 0.153
6 A G A G G G 0.050 0.053
7 T A G G A A 0.120 0.127
Rare haplotypes 0.001 0.002
COPD: chronic obstructive pulmonary disease.
c
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Beyond the ‘‘ABC approach’’
To the Editors:
I read with interest the recent review by CELLI and BARNES [1],
wherein the authors have beautifully discussed the aetiology,
cellular and molecular mechanisms, management and new
definition of exacerbations of chronic obstructive pulmonary
disease (COPD).
In the management of acute exacerbations of COPD they have
discussed the role of three classes of drugs (antibiotics,
bronchodilators and corticosteroids, i.e. an ‘‘ABC approach’’);
however, the role of oxygen therapy, theophylline and
supportive management is not mentioned. All of these have
implications for the management of the disease.
Hypoxia at exacerbation of COPD is quite common and may be
life threatening. The importance of controlled oxygen therapy
during the management of acute exacerbation cannot be
overlooked [2].
Theophylline is widely used in the management of stable
patients with COPD. A recent meta-analysis evaluating the role
of intravenous aminophylline in cases of acute exacerbation of
COPD did not find any beneficial effect in terms of improve-
ment of pulmonary function or symptoms [3]. However, the
withdrawal of methylxanthines in patients already receiving
them can worsen lung function, clinical status, exercise
performance and ratings of dyspnoea [4]. Therefore, patients
already receiving oral preparations of methylxanthines for
stable disease should continue on such treatments at the time
of exacerbation. The current Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines even suggest
adding aminophylline to standard therapy for patients with
moderate-to-severe exacerbations or those not responding to
nebulised short-acting bronchodilators [5].
Appropriate fluid balance (with special attention to the
administration of diuretics), nutritional aspects, anticoagulants,
and cardiovascular agents are the most complementary stan-
dard measures. Manual or mechanical chest percussion and
postural drainage may be beneficial in patients producing
.25 mL sputum per day or with lobar atelectasis.
A. Singh
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